The administration of the Imvanex vaccine towards smallpox mpox to adolescents aged between 12 and 17 was authorized by the European Fee following the advice of the European Medicines Company (EMA), with the Commissioner for Well being and Meals Security of the EU, Stella Kyriakidou, making a speech for a “vital step ahead”.
“Whereas the general threat of monkeypox an infection to the overall EU inhabitants stays low, we’re continually working at EU stage to make sure we’re nicely ready,” famous Ms Kyriakidou, referring to the collaboration with the European Heart for Prevention and Management (ECDC), EU member states, the World Well being Group (WHO), the African Union and the African Heart for Illness Management and Prevention (Africa CDC) to manage the unfold of mpox on the African continent.
“Solely by international cooperation can we overcome well being emergencies,” he harassed.
Imvanex is the one monkeypox vaccine presently authorized within the EU, together with the antiviral therapy (Tecovirimat SIGA).
The vaccine was first authorized within the EU in 2013 to guard adults towards smallpox. The approval was prolonged in 2022 to cowl the safety of adults towards mpox.
Given the significance of the vaccine, particularly for Africa, the EMA prioritized the analysis course of to find out whether or not the vaccine will be administered to adolescents, and the Fee authorized the vaccine by an accelerated process. EMA continues to work with African regulatory authorities to advertise vaccine approval in Africa.
Supply: KYPE
